Class Action Lawsuit Announced Against Soleno Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 10 2026
0mins
Source: Globenewswire
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Soleno Therapeutics (NASDAQ: SLNO) for common stock purchasers between March 26 and November 4, 2025, indicating potential investor losses due to undisclosed risks.
- Compensation Structure: Participants in the class action may receive compensation without any out-of-pocket fees, highlighting the accessibility of legal services and the protection of investor rights in securities litigation.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety evidence related to its DCCR drug clinical trials, which could lead investors to misjudge the company's future commercial viability and associated risks.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
